Frederic Moll Net Worth

The estimated Net Worth of Frederic H Moll is at least $18.1 Million dollars as of 9 August 2018. Frederic Moll owns over 333,333 units of Intersect ENT stock worth over $16,885,331 and over the last 16 years he sold XENT stock worth over $1,055,742. In addition, he makes $172,839 as Independent Director at Intersect ENT.

Frederic Moll XENT stock SEC Form 4 insider trading

Frederic has made over 13 trades of the Intersect ENT stock since 2003, according to the Form 4 filled with the SEC. Most recently he bought 333,333 units of XENT stock worth $500,000 on 9 August 2018.

The largest trade he’s ever made was buying 333,333 units of Intersect ENT stock on 9 August 2018 worth over $500,000. On average, Frederic trades about 10,326 units every 134 days since 2003. As of 9 August 2018 he still owns at least 929,809 units of Intersect ENT stock.

You can see the complete history of Frederic Moll stock trades at the bottom of the page.

Frederic Moll biography

Dr. Frederic H. Moll, M.D., is the Independent Director of Intersect ENT, Inc. Dr. Moll has served as a member of our Board of Directors since March 2006. Dr. Moll was the Chief Executive Officer and Chairman of Auris Surgical Robotics, Inc. from August 2012 and June 2011, respectively, through its acquisition by Ethicon, a Johnson & Johnson company, in April 2019, and Dr. Moll is now the Chief Development Officer of Johnson & Johnson. Since 2011, Dr. Moll has also served on the Board of Directors of ShockWave Medical, Inc., a medical device company. Dr. Moll has served on the Board of Directors of Biolase, Inc., a dental laser company, from June 2013 until November 2017, and on the Board of Directors of Hansen Medical, Inc., or Hansen, a surgical robotics company, from September 2002 until December 2011. Dr. Moll also served as Executive Chairman of the Board of Hansen from June 2010 until December 2011, as Chief Executive Officer from September 2002 until June 2010, and President from March 2009 until June 2010. Dr. Moll was a director of MAKO Surgical Corp. until its acquisition in December 2013. Moll’s experience as a physician, chief executive officer of medical technology companies and his knowledge of our company and the industry enable him to make valuable contributions to our Board of Directors.

What is the salary of Frederic Moll?

As the Independent Director of Intersect ENT, the total compensation of Frederic Moll at Intersect ENT is $172,839. There are 10 executives at Intersect ENT getting paid more, with Jeryl Hilleman having the highest compensation of $1,611,920.

How old is Frederic Moll?

Frederic Moll is 67, he’s been the Independent Director of Intersect ENT since 2006. There are no older and 12 younger executives at Intersect ENT.

What’s Frederic Moll’s mailing address?

Frederic’s mailing address filed with the SEC is C/O RESTORATION ROBOTICS, INC., 128 BAYTECH DRIVE, SAN JOSE, CA, 95134.

Insider trading at Intersect ENT

Over the last 5 years, insiders at Intersect ENT have traded over $22,113,703 worth of Intersect ENT stock and bought 24,811 units worth $387,714 . The most active insider traders include Rick D Anderson, Lisa D Earnhardt, and W Anthony Vernon. On average, Intersect ENT executives and independent directors trade stock every 14 days with the average trade being worth of $262,225. The most recent stock trade was executed by Susan P Stimson on 13 June 2019, trading 350 units of XENT stock currently worth $4,568.

What does Intersect ENT do?

Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA.

What does Intersect ENT’s logo look like?

Complete history of Frederic Moll stock trades at BIOLASE, Intersect ENT, Intuitive Surgical, and Restoration Robotics

Intersect ENT executives and stock owners

Intersect ENT executives and other stock owners filed with the SEC include:

  • Jeryl Hilleman, Chief Financial Officer
  • Drake Parker, Advisor – Strategic Initiatives
  • David Lehman, General Counsel
  • Gwen Carscadden, Chief People Officer
  • Kieran Gallahue, Executive Chairman of the Board
  • Cynthia Lucchese, Independent Director
  • Dana Mead, Independent Director
  • Teresa Kline, Independent Director
  • William Vernon, Independent Director
  • Frederic Moll, Independent Director
  • Christine Kowalski, Chief Operating Officer
  • Thomas West, President, Chief Executive Officer, Director
  • W Anthony Vernon, Director
  • Lisa D Earnhardt,
  • Casey M Tansey, Director
  • Amy Wolbeck, See Remarks
  • Susan P Stimson, Vice President, Marketing
  • Richard E Kaufman, See Remarks
  • Robert H Jr Binney, Vice President, Sales
  • Rick D Anderson, Director
  • Sciences Ii L P Pinto Techn…,
  • Clercq Casper L. De, Director
  • Sciences Ii L P Pinto Techn…,
  • Perkins Caufield & Byers Xi…,
  • James Stambaugh, VP, Clinical and Reimbursement
  • Chas Mc Khann, Chief Commercial Officer
  • Mark J Fletcher, Director
  • Management Group Ix, L.L.C….,
  • Venture Partners Xi, Lp Nor…,